The CBFA2T3 antibody is designed to target the CBFA2T3 protein, encoded by the CBFA2T3 gene (also known as MTG16 or ETO2), which belongs to the ETO family of nuclear corepressors. This protein plays a critical role in transcriptional regulation, particularly in hematopoiesis and cellular differentiation, by forming complexes with chromatin-modifying enzymes and transcription factors to repress gene expression. CBFA2T3 is notably involved in chromosomal translocations associated with acute myeloid leukemia (AML), such as the t(8;21)(q22;q22) translocation that fuses CBFA2T3 with RUNX1. resulting in the RUNX1-CBFA2T3 oncoprotein. This fusion disrupts normal transcriptional programs, promoting leukemogenesis. Antibodies against CBFA2T3 are widely used in research to study its expression, localization, and interaction partners in both normal and malignant cells. They are essential tools in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation, aiding in the characterization of its role in cancer biology and developmental processes. Additionally, these antibodies have potential diagnostic and therapeutic relevance, particularly in identifying AML subtypes and exploring targeted therapies for CBFA2T3-related malignancies.